Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content for NCT02708641, indicating access is blocked. This reflects an access/error condition rather than a content update.
    Difference
    18%
    Check dated 2026-09-20T22:40:34.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page revision label updated from v3.6.5 to v3.6.6, indicating a minor template/backend update. No study content or data are changed.
    Difference
    0.1%
    Check dated 2026-08-30T15:46:22.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.6.5 was added to the page, indicating an updated version of the study record display. Older study-record items and documents (e.g., PDFs, past posting dates, and related links) were removed from the page.
    Difference
    17%
    Check dated 2026-08-09T00:16:52.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.3 to v3.6.4, indicating a software release. There are no visible changes to the study content or page functionality beyond the metadata.
    Difference
    0.1%
    Check dated 2026-07-25T17:14:48.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    A new revision tag v3.6.3 replaced v3.6.2 on the page. This indicates a small update to the page template or content management.
    Difference
    0.1%
    Check dated 2026-07-04T13:26:55.000Z thumbnail image
  8. Check
    97 days ago
    Change Detected
    Summary
    The page revision has been updated from v3.6.0 to v3.6.2, indicating a minor backend/UI update. This change does not alter the study details or their presentation to users.
    Difference
    0.1%
    Check dated 2026-06-27T05:51:29.000Z thumbnail image

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.